Neurocrine Net Tangible Assets vs Total Assets Analysis
NBIX Stock | USD 136.99 1.57 1.16% |
Neurocrine Biosciences financial indicator trend analysis is infinitely more than just investigating Neurocrine Biosciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neurocrine Biosciences is a good investment. Please check the relationship between Neurocrine Biosciences Net Tangible Assets and its Total Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.
Net Tangible Assets vs Total Assets
Net Tangible Assets vs Total Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neurocrine Biosciences Net Tangible Assets account and Total Assets. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Neurocrine Biosciences' Net Tangible Assets and Total Assets is 0.97. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Total Assets in the same time period over historical financial statements of Neurocrine Biosciences, assuming nothing else is changed. The correlation between historical values of Neurocrine Biosciences' Net Tangible Assets and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Neurocrine Biosciences are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Net Tangible Assets i.e., Neurocrine Biosciences' Net Tangible Assets and Total Assets go up and down completely randomly.
Correlation Coefficient | 0.97 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Total Assets
Total assets refers to the total amount of Neurocrine Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Neurocrine Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Most indicators from Neurocrine Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neurocrine Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.At this time, Neurocrine Biosciences' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 63.8 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 22.9 M in 2024.
Neurocrine Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Neurocrine Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neurocrine Biosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.3B | 1.7B | 2.1B | 2.4B | 3.3B | 3.4B | |
Short Long Term Debt Total | 817.6M | 412.3M | 440.4M | 262.9M | 428.4M | 449.8M | |
Other Current Liab | 156.5M | 147.1M | 194.3M | 292M | 351.4M | 369.0M | |
Total Current Liabilities | 565.3M | 186.5M | 245.8M | 537.7M | 654.8M | 687.5M | |
Total Stockholder Equity | 636.9M | 1.1B | 1.4B | 1.7B | 2.2B | 2.3B | |
Property Plant And Equipment Net | 116.2M | 127.4M | 155.8M | 145.6M | 347.3M | 364.7M | |
Net Debt | 383.2M | (388.7M) | 99.6M | 169.4M | 177.3M | 186.2M | |
Retained Earnings | (1.1B) | (725.4M) | (635.8M) | (406.8M) | (157.1M) | (165.0M) | |
Accounts Payable | 46.2M | 39.4M | 51.5M | 67.3M | 108.9M | 114.3M | |
Cash | 112.3M | 801M | 340.8M | 262.9M | 251.1M | 131.9M | |
Non Current Assets Total | 475M | 718.5M | 1.1B | 915.2M | 1.6B | 1.7B | |
Non Currrent Assets Other | 3.2M | 6.4M | 4.4M | 25M | 49.6M | 52.1M | |
Cash And Short Term Investments | 670.5M | 801M | 711.3M | 989.3M | 1.0B | 1.1B | |
Net Receivables | 126.6M | 157.1M | 185.5M | 350M | 439.3M | 461.3M | |
Common Stock Shares Outstanding | 95.7M | 97.8M | 97.9M | 98.9M | 101M | 61.8M | |
Liabilities And Stockholders Equity | 1.3B | 1.7B | 2.1B | 2.4B | 3.3B | 3.4B | |
Non Current Liabilities Total | 103.8M | 422M | 452.7M | 123.2M | 364.6M | 382.8M | |
Other Current Assets | 160.5M | 30.1M | 45.5M | 79.1M | 97.8M | 102.7M | |
Other Stockholder Equity | 1.8B | 1.8B | 2.0B | 2.1B | 2.4B | 2.5B | |
Total Liab | 669.1M | 608.5M | 698.5M | 660.9M | 1.0B | 1.1B | |
Property Plant And Equipment Gross | 116.3M | 127.4M | 155.8M | 145.6M | 430.3M | 451.8M | |
Total Current Assets | 831M | 1.0B | 972.8M | 1.5B | 1.6B | 1.7B | |
Accumulated Other Comprehensive Income | 1.4M | 1.8M | (1.7M) | (7.9M) | 7M | 7.4M | |
Short Term Debt | 408.8M | 10.3M | 16.5M | 169.4M | 170.1M | 178.6M | |
Short Term Investments | 558.2M | 613.9M | 370.5M | 726.4M | 780.5M | 819.5M | |
Other Liab | 17.1M | 9.7M | 12.3M | 29.7M | 34.2M | 24.8M | |
Other Assets | 59.1M | 674M | 319.5M | 330.9M | 380.5M | 399.6M | |
Long Term Debt | 388.5M | 408.8M | 317.9M | 335.1M | 385.4M | 404.6M | |
Common Stock Total Equity | 89K | 91K | 92K | 100K | 115K | 67.8K | |
Common Stock | 89K | 91K | 92K | 100K | 115K | 69.6K | |
Property Plant Equipment | 33.9M | 41.9M | 44.6M | 58.6M | 52.7M | 55.4M | |
Current Deferred Revenue | (46.2M) | (10.3M) | (16.5M) | 229.3M | 263.7M | 276.9M | |
Net Tangible Assets | 228.1M | 1.1B | 1.4B | 1.7B | 1.9B | 2.0B | |
Retained Earnings Total Equity | (1.1B) | (725.4M) | (635.8M) | (406.8M) | (366.1M) | (384.4M) | |
Capital Surpluse | 1.8B | 1.8B | 2.0B | 2.1B | 2.4B | 1.6B | |
Inventory | 17.3M | 28M | 30.5M | 35.1M | 38.3M | 40.2M | |
Non Current Liabilities Other | 103.8M | 104.1M | 117.6M | 29.7M | 10.3M | 9.8M | |
Long Term Investments | 299.7M | 227.1M | 560.7M | 401.5M | 849.4M | 891.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.